System barriers to the appropriate, timely, and equitable use of biomedical innovations have led to slow and inconsistent adoption, limiting their full potential impact on patient outcomes. For 16 years … Read More
Nature Reviews Drug Discovery: Clinical development success rates for durable cell and gene therapies
Our article compares the clinical development success rates of durable cell and gene therapies (dCGTs) from 1988 to 2023 with BIO and IQVIA’s published benchmarks for all therapeutic modalities. As … Read More
Nature Reviews Drug Discovery: Clinical development success rates for durable cell and gene therapies
Our article compares the clinical development success rates of durable cell and gene therapies (dCGTs) from 1988 to 2023 with BIO and IQVIA’s published benchmarks for all therapeutic modalities. As … Read More
Health Affairs Forefront: Bringing Systems Thinking to Drug Value Assessment
Drug value assessments generally fail to account for the complexities of health care systems and thus can misinform price negotiations and lead to overly restrictive access policies. Our [new article … Read More
Health Affairs Forefront: Bringing Systems Thinking to Drug Value Assessment
Drug value assessments generally fail to account for the complexities of health care systems and thus can misinform price negotiations and lead to overly restrictive access policies. Our [new article … Read More
Implementation Brief: Implementing an innovative contract
The contract is signed—now what? Next, stakeholders must prepare to implement the innovative contract. This brief offers a checklist of potential considerations for executing the agreement, including aligning stakeholders and … Read More
Implementation Brief: Designing an innovative contract
Once the decision has been made to move forward with an innovative contract for a specific medical treatment, the details of a contract must be designed. This brief offers a … Read More
Implementation Brief: Is innovative contracting right for you?
Innovative contracts can offer significant benefits for stakeholders delivering novel drugs and medical products to patients — but they require resources to design and implement. This Implementation Brief outlines key … Read More
Managing the challenges of paying for gene therapy: strategies for market action and policy reform in the United States
New open access policy analysis from Institute for Clinical and Economic Review (ICER) and NEWDIGS Initiative at Tufts Medical Center analyzes the challenges and potential policy options for paying for … Read More
Implementation Brief: Innovative contracting 101
This brief provides an introduction to innovative contracts, or value-based contracts, which may be used to facilitate access to innovative, high-cost treatments. These contracts can address uncertainty around treatments and … Read More